Top25-SA-Banner

Analysts Offer Insights on Healthcare Companies: Conatus Pharmaceuticals (CNAT) and HTG Molecular Diagnostics (HTGM)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Conatus Pharmaceuticals (CNAT) and HTG Molecular Diagnostics (HTGM) with bullish sentiments.

Conatus Pharmaceuticals (CNAT)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Conatus Pharmaceuticals, with a price target of $14. The company’s shares closed on Tuesday at $4.50.

Arce said:

“916-3963, Probability of success (POS) Prob-adj Value Full value POLT, U.S. 55% $1.02 $1.85 Shares outstanding 30,262 25, 2018. Emricasan for cirrhosis, U.S.”

According to TipRanks.com, Arce is a 4-star analyst with an average return of 10.1% and a 38.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.

Conatus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $9.67, which is an 114.9% upside from current levels. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $10 price target.

.

See today’s analyst top recommended stocks >>

HTG Molecular Diagnostics (HTGM)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics, with a price target of $8. The company’s shares closed on Tuesday at $3.43.

Selvaraju commented:

“Our price target is derived from a market value of the firm at $222M excluding debt. This includes a discounted cash flow analysis based asset value at $231M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate.”

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.3% and a 24.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for HTG Molecular Diagnostics with a $7.10 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.